Tempest Therapeutics partners with Senlang Biotech to advance TPST-4003 in vivo CAR-T into first-in-human trial - TPST News | RalliesTempest Therapeutics partners with Senlang Biotech to advance TPST-4003 in vivo CAR-T into first-in-human trial
T
TPST• Tempest Therapeutics and Senlang Biotech collaboration
- Tempest Therapeutics entered a development collaboration with Senlang Biotechnology to advance TPST-4003, an in vivo CAR-T candidate.
- Senlang will run a first-in-human investigator-initiated trial in China in about 10 patients with myasthenia gravis or multiple sclerosis.
- First patient dosing is expected in Q4 2026; initial safety and pharmacodynamic readouts are expected in H1 2027.
- Senlang received an exclusive option to negotiate a China license for TPST-4003.
